Illumina, Inc. (ILMN)
Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Illumina (ILMN) Could Beat Earnings Estimates Again
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wall Street Analysts Think Illumina (ILMN) Could Surge 27.02%: Read This Before Placing a Bet
The consensus price target hints at a 27% upside potential for Illumina (ILMN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Illumina (ILMN) Upgraded to Buy: Here's Why
Illumina (ILMN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Strategic Buy Lights Up This Biotech Stock: Time to Invest?
Life sciences company Illumina Inc. NASDAQ: ILMN stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. This comes after its divestiture and spin-off of GRAIL, LLC NASDAQ: GRAL on June 24, 2024.
What's Happening With Illumina Stock?
Illumina stock (NASDAQ: ILMN) saw a 6% rise on Wednesday, July 10, faring better than its peer — Mettler-Toledo stock – up 1%. The rise in ILMN stock can primarily be attributed to the company's acquisition of Fluent Biosciences to expand its single-cell analysis and multiomics offerings.
What's Going On With 10x Genomics Stock On Wednesday?
Wednesday, Illumina Inc ILMN acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research for an undisclosed consideration.
Illumina Buys Fluent BioSciences To Gain Stronger Foothold In Single-Cell Analysis
Last month, Illumina Inc ILMN had to let go of Grail Inc. Still, the DNA sequencing company has acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research.
Illumina (ILMN) Buys Fluent, Grows in Single Cell Research
By integrating Fluent's unique technology with Illumina's (ILMN) sequencing and informatics solutions, researchers are likely to gain access to a comprehensive solution for single-cell multiomic analysis.
Illumina Takes a $1.47 Billion Charge Related to Its Spinoff of GRAIL
The breakup with GRAIL (GRAL) was costly for Illumina (ILMN).
Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out
Illumina has finally completed the divestiture of GRAIL, ending a disastrous chapter in its history. The Company paid $8bn to acquire the cancer testing business it helped to create, which proved to be a disastrous mistake, triggering three years of share price losses. Newly spun-out GRAIL faces challenges in the competitive cancer testing market, while Illumina returns to its profitable gene sequencing business.
Illumina to take $1.47 bln goodwill impairment charge related to Grail in Q2
Illumina said on Thursday it will take a goodwill impairment charge of $1.47 billion in the second quarter related to the recently spun-off Grail Inc.
